Blasco-Iturri, Z. (Zuriñe)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
3 results
Search Results
Now showing 1 - 3 of 3
- Determinación de enfermedad mínima residual molecular en sangre periférica mediante NGS como nueva herramienta en el seguimiento posttrasplante alogénico de progenitores hematopoyéticos(2019) Fernandez-Mercado, M. (Marta); Aguilera-Díaz, A. (Almudena); Arnedo, P. (P.); Bandres, E. (Eva); Viguria, M.C. (María C.); Aguirre-Ruiz, P. (P.); Zudaire, M.T. (Maria Teresa); Redondo, M. (M.); Vazquez, I. (Iria); Larrayoz, M.J. (María J.); Jauregui, A. (A.); Prosper-Cardoso, F. (Felipe); Mateos, M.C. (María C.); Blasco-Iturri, Z. (Zuriñe); Calasanz-Abinzano, M.J. (Maria Jose)La determinación de la EMR en médula ósea y del quimerismo hematopoyético (QH) en sangre periférica (SP), son herramientas imprescindibles para detectar recaídas en el seguimiento post-alo-TPH. La combinación de tecnologías más sensibles, que identifiquen cambios en el QH, y más específicos que detecten recaídas en sangre periférica, pueden complementar los estudios de EMR realizados en médula ósea (MO) y permitir tomar decisiones clínicas más precoces y específicas. El objetivo de este estudio fue valorar la aplicabilidad clínica de determinar la EMR molecular mediante Next Generation Sequencing (NGS) en SP en aquellos momentos en los que se observa un cambio del QH.
- Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design(2020) Ariceta, B. (Beñat); Fernandez-Mercado, M. (Marta); Aguilera-Díaz, A. (Almudena); Prieto-Conde, M.I. (María Isabel); García-Sanz, R. (Ramón); Palomino-Echeverría, S. (Sara); Mañú, A. (Amagoia); Alfonso-Piérola, A. (Ana); Vazquez, I. (Iria); Larrayoz, M.J. (María J.); Prosper-Cardoso, F. (Felipe); Chillón, M.C. (María del Carmen); Blasco-Iturri, Z. (Zuriñe); Calasanz-Abinzano, M.J. (Maria Jose)The diagnosis of myeloid neoplasms (MN) has significantly evolved through the last few decades. Next Generation Sequencing (NGS) is gradually becoming an essential tool to help clinicians with disease management. To this end, most specialized genetic laboratories have implemented NGS panels targeting a number of different genes relevant to MN. The aim of the present study is to evaluate the performance of four different targeted NGS gene panels based on their technical features and clinical utility. A total of 32 patient bone marrow samples were accrued and sequenced with 3 commercially available panels and 1 custom panel. Variants were classified by two geneticists based on their clinical relevance in MN. There was a difference in panel¿s depth of coverage. We found 11 discordant clinically relevant variants between panels, with a trend to miss long insertions. Our data show that there is a high risk of finding different mutations depending on the panel of choice, due both to the panel design and the data analysis method. Of note, CEBPA, CALR and FLT3 genes, remains challenging the use of NGS for diagnosis of MN in compliance with current guidelines. Therefore, conventional molecular testing might need to be kept in place for the correct diagnosis of MN for now.
- Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms(MDPI AG, 2020) Ariceta, B. (Beñat); Fernandez-Mercado, M. (Marta); Aguilera-Díaz, A. (Almudena); Arnedo, P. (P.); Bandres, E. (Eva); Cruz-Viguria, M. (Maria); Aguirre-Ruiz, P. (P.); Mañú, A. (Amagoia); Zudaire, M.T. (Maria Teresa); Redondo, M. (M.); Vazquez, I. (Iria); Larrayoz, M.J. (María J.); Jauregui, A. (A.); Prosper-Cardoso, F. (Felipe); Mateos, M.C. (María C.); Blasco-Iturri, Z. (Zuriñe); Calasanz-Abinzano, M.J. (Maria Jose)Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed. We hypothesized that the use of next generation sequencing (NGS) could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR) chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable for the evaluation of patients following HSCT and highly valuable to personalized early treatment intervention when mixed chimerism is detected.